Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Heard: Bill to protect 340B drug program access draws broad, divided testimony
Summary
SB 5,981 would prohibit manufacturers from restricting acquisition or delivery of 340B drugs to covered entities or contract pharmacies (unless federal law requires such limits) and would bar manufacturers from demanding claims or utilization data as a condition of participation; hospital systems, community health centers, tribal clinics and manufacturers offered sharply divergent testimony.
Senate Bill 5,981 drew extended testimony Jan. 16. The bill would prohibit drug manufacturers or distributors from denying, restricting or prohibiting acquisition or delivery of a 340B drug by a covered entity or a contract pharmacy unless federal law requires such restriction, and would bar manufacturers from conditioning 340B access on submission of claims, utilization or purchasing data unless federal law requires it. The bill would allow…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
